| Gene/axis | Core clinical spectrum labels | Primary developmental cell types/processes | Variant classes & proposed mechanisms | Key evidence snippets | Suggested dismech entry modeling | Notes/uncertainties |
|---|---|---|---|---|---|---|
| PAX3 | WS1; WS3/Klein-Waardenburg; craniofacial-deafness-hand syndrome; overlaps with some clinically WS2-like cases lacking dystopia canthorum | Neural crest specification/migration; melanocyte development; craniofacial and limb development; upstream control of MITF; contribution to cochlear melanocyte/stria vascularis biology via melanocyte lineage | Core mechanism is LoF/haploinsufficiency for many truncating/deletion alleles; DNA-binding missense in paired/homeodomain disrupt transcriptional regulation; some paired-domain missense likely dominant-negative/target-selective and can produce distinct syndromes | “PAX3 is described as the cause restricted to WS1 and WS3” (pqac-00000001); “PD mutations alter the DNA binding activity of PAX3 proteins” and HD mutations “obstruct…binding of PAX3 to DNA” (pqac-00000009); “asparagine 47 is changed to histidine in WS3” vs “lysine in craniofacial-deafness-hand syndrome”; some mutations “may be dominant-negative” (pqac-00000015) | **Separate gene-axis spectrum entry** for PAX3-Waardenburg spectrum; include internal sub-spectrum labels for WS1, WS3, craniofacial-deafness-hand; cross-link to MITF/SOX10 melanocyte regulatory network and to hearing-loss/stria vascularis module | Penetrance/expressivity are variable; no simple mutation-position→severity rule overall; clinically some PAX3 carriers can lack classic dystopia canthorum, so phenotype-only split is imperfect (pqac-00000007, pqac-00000008) |
| SOX10 | WS2E; WS4C; PCWH/PCW; neurologic/neurocristopathy spectrum including peripheral neuropathy, central dysmyelination/leukodystrophy; Kallmann/anosmia features in some reports | Neural crest survival/multipotency; melanocyte specification; ENS development; Schwann-cell and oligodendrocyte differentiation/myelination; regulation of MITF, EDNRB, RET | Two major mechanism bins: (1) haploinsufficiency/LoF from deletions and truncations subject to NMD; (2) truncating variants in last coding exon / end of penultimate exon that escape NMD, producing dominant-negative or toxic/altered GoF effects linked to more severe neurologic/PCWH phenotypes; deleterious missense can disrupt localization, DNA binding, transactivation | “partial/full gene deletions indicate haploinsufficiency” (pqac-00000012); last-exon truncations “escape NMD so mutant protein is produced and acts dominant-negative” and are linked to severe PCWH (pqac-00000012); SOX10 “regulates melanocyte genes (MITF…); enteric regulators (EDNRB, RET) and glial/myelination genes” (pqac-00000014); SOX10 variants are associated with “higher risk…auditory system diseases and nervous system diseases” (pqac-00000006) | **Separate gene-axis spectrum entry** for SOX10 neurocristopathy spectrum; keep/expand existing PCWH entry as a **variant-class/mechanism-defined subentry** under SOX10 rather than isolated disease silo; cross-link to MITF module and EDN3/EDNRB Waardenburg-Shah axis | Strongest evidence for mechanism split is by NMD status/variant position; some papers frame severe alleles as dominant-negative, others as toxic/altered GoF, so mechanism wording should be flagged as partly disputed; Hirschsprung may be absent even with neuropathy (pqac-00000012, pqac-00000014) |
| EDNRB | WS4A; heterozygous WS2-like/WS1-like auditory-pigmentary presentations in some families; isolated Hirschsprung overlap | Endothelin receptor signaling in melanoblast and enteric neural crest survival/proliferation/migration/differentiation; inner-ear melanocyte pathway relevant to hearing | Canonical biallelic LoF for WS4/HSCR overlap; heterozygous LoF can confer incompletely penetrant WS2-like or HSCR susceptibility; dosage-sensitive / semidominant inheritance pattern; receptor missense can impair trafficking, ligand binding, signaling | EDN3/EDNRB are “important for survival, proliferation, migration and/or differentiation of melanoblasts and for enteric progenitor regulation” (pqac-00000005); heterozygous EDNRB variants in WS2 show “dominant mode with incomplete penetrance” and explain “~5–6% of WS2” (pqac-00000005); pattern is “not fully dominant not fully recessive” (pqac-00000005, pqac-00000013) | **Separate EDNRB entry or combined EDN3–EDNRB signaling-axis entry**; preferred modeling: keep **distinct gene pages cross-linked under one Waardenburg-Shah signaling axis**, because gene-level evidence and inheritance differ; cross-link to isolated HSCR mechanism entries | Evidence supports heterozygous risk but penetrance is low/incomplete; some WS subtype assignments in literature are inconsistent; avoid overcommitting to EDNRB as a common WS1 cause despite occasional reports (pqac-00000005, pqac-00000013) |
| EDN3 | WS4B; Shah-Waardenburg; isolated Hirschsprung overlap, especially with heterozygous susceptibility alleles in some families | Endothelin ligand controlling melanoblast and enteric neural crest proliferation/migration/survival through EDNRB; contributes to auditory-pigmentary phenotype via melanocyte lineage | Mainly autosomal recessive/biallelic LoF for WS4 spectrum; heterozygous effects can occur with incomplete penetrance / dosage-sensitive semidominant pattern in some families; ligand-processing defects reported | “EDN3 is listed as AR (with AD mutations causing HSCR only)” (pqac-00000002); EDN3/EDNRB inheritance can be “not fully recessive and not fully dominant” (pqac-00000013); EDN3 missense can impair processing, e.g. mutations that abolish mature ET3 production (pqac-00000013) | **Separate EDN3 entry or combined EDN3–EDNRB signaling-axis entry**; preferred modeling: **paired axis module** with EDNRB, but retain distinct gene-specific mechanism notes because ligand vs receptor defects are not identical | EDN3 has weaker evidence than EDNRB for heterozygous WS-only presentations; better treated as part of Waardenburg-Shah signaling axis with explicit AR-first weighting and semidominant caveat (pqac-00000002, pqac-00000013) |
| MITF | WS2A; Tietz syndrome / albinism-deafness spectrum; possible blended Waardenburg/Tietz presentations | Melanocyte specification, survival, melanin synthesis; melanocyte contribution to stria vascularis/intermediate cells and hearing | Established LoF/haploinsufficiency for many nonsense/CNV alleles causing WS2A; dominant-negative missense mechanism important for some Tietz and severe MITF alleles; possible dosage/structural GoF for rare duplications | MITF mutations cause “WS2 and Tietz syndrome” (pqac-00000002); last-exon MITF nonsense variant: “mechanism for the disease is likely to be haploinsufficiency” (pqac-00000004); MITF duplication proposed to cause “a gain-of-function with increased protein dosage” (pqac-00000007) | **Retain separate MITF Waardenburg/Tietz entry**, but update to an explicit **MITF auditory-pigmentary spectrum** with mechanism branches (WS2A-haploinsufficiency vs Tietz/dominant-negative or severe altered-function alleles); cross-link upstream regulators PAX3 and SOX10 | 2024 Tietz dominant-negative report exists but was unobtainable here, so strong recent support is indirect; current entry should flag variant-class heterogeneity and avoid assuming one mechanism for all MITF syndromic deafness alleles (pqac-00000004, pqac-00000007) |
| SNAI2 | Historically proposed WS2D / piebaldism-like phenotype; currently best viewed as unconfirmed/emerging hypothesis | Neural crest / melanocyte development module note | Insufficiently established; legacy reports suggested deletion/LoF, but re-evaluation questions original technical findings | “we now doubt the claimed associations of SNAI2 deletions with piebaldism and Waardenburg syndrome” (pqac-00000015 via Mirhadi letter context pqac-00000015? actually direct SNAI2 doubt is in pqac-00000015-adjacent evidence not table-specific; strongest available: “earlier SNAI2 findings were retracted as artifacts” (pqac-00000001)) | **Do not create standalone disease-mechanism entry**; keep as **module note / emerging-limited evidence hypothesis** linked to melanocyte/neural crest regulatory network | Evidence is disputed and may reflect obsolete methods/artifact; unless independent modern genomic confirmation emerges, SNAI2 should remain non-core for Waardenburg curation (pqac-00000001) |


*Table: This table summarizes gene- and axis-level evidence for modeling Waardenburg syndrome mechanisms in dismech. It highlights where separate spectrum entries are justified, where cross-linked signaling-axis modeling is preferable, and where evidence remains too limited for standalone curation.*